The Significance of α-Synuclein, Amyloid-β and Tau Pathologies in Parkinsn's Disease Progression and Related Dementia

被引:73
|
作者
Compta, Yaroslau [1 ]
Parkkinen, Laura [4 ]
Kempster, Peter [2 ,3 ]
Selikhova, Mariana [5 ]
Lashley, Tammaryn [5 ]
Holton, Janice L. [5 ]
Lees, Andrew J. [5 ]
Revesz, Tamas [5 ]
机构
[1] Hosp Clin Barcelona, CIBERNED, Parkinson Dis & Movement Disorders Unit, Neurol Serv,IDIBAPS, Barcelona, Spain
[2] Monash Med Ctr, Dept Neurosci, Melbourne, Vic, Australia
[3] Monash Univ, Melbourne, Vic 3004, Australia
[4] Univ Oxford, Oxford Parkinsons Dis Ctr, Nuffield Dept Clin Neurosci, Oxford, England
[5] UCL, Inst Neurol, Dept Mol Neurosci, Queen Sq Brain Bank Neurol Disorders, London, England
基金
英国医学研究理事会; 英国惠康基金;
关键词
Parkinson's disease; Dementia; Lewy-type pathology; Alzheimer-type pathology; alpha-Synuclein; Tau; Amyloid-beta; Biomarkers; A-BETA; ALZHEIMER-PATHOLOGY; COGNITIVE DECLINE; LEWY; DEPOSITION; RISK; CSF; MARKERS; LOAD;
D O I
10.1159/000354670
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Dementia is one of the milestones of advanced Parkinson's disease (PD), with its neuropathological substrate still being a matter of debate, particularly regarding its potential mechanistic implications. Objective: The aim of this study was to review the relative importance of Lewy-related alpha-synuclein and Alzheimer's tau and amyloid-beta (A beta) pathologies in disease progression and dementia in PD. Methods: We reviewed studies conducted at the Queen Square Brain Bank, Institute of Neurology, University College London, using large PD cohorts. Results: Cortical Lewy- and Alzheimer-type pathologies are associated with milestones of poorer prognosis and with non-tremor predominance, which have been, in turn, linked to dementia. The combination of these pathologies is the most robust neuropathological substrate of PD-related dementia, with cortical A beta burden determining a faster progression to dementia. Conclusion: The shared relevance of these pathologies in PD progression and dementia is in line with experimental data suggesting synergism between a-synuclein, tau and A beta and with studies testing these proteins as disease biomarkers, hence favouring the eventual testing of therapeutic strategies targeting these proteins in PD. (C) 2013 S. Karger AG, Basel
引用
收藏
页码:154 / 156
页数:3
相关论文
共 50 条
  • [21] Significant Overlap of α-Synuclein, Amyloid-β, and Phospho-Tau Pathologies in Neuropathological Diagnosis of Lewy-related Pathology: Evidence from China Human Brain Bank
    Cong, Cong
    Zhang, Wanying
    Qian, Xiaojing
    Qiu, Wenying
    Ma, Chao
    JOURNAL OF ALZHEIMERS DISEASE, 2021, 80 (01) : 447 - 458
  • [22] Convergence of Amyloid-β and Tau Pathologies on Mitochondria In Vivo
    Eckert, Anne
    Schulz, Kathrin L.
    Rhein, Virginie
    Goetz, Juergen
    MOLECULAR NEUROBIOLOGY, 2010, 41 (2-3) : 107 - 114
  • [23] Amyloid-β and Parkinson's disease
    Lim, Ee Wei
    Aarsland, Dag
    Ffytche, Dominic
    Taddei, Raquel Natalia
    van Wamelen, Daniel J.
    Wan, Yi-Min
    Tan, Eng King
    Chaudhuri, Kallol Ray
    JOURNAL OF NEUROLOGY, 2019, 266 (11) : 2605 - 2619
  • [24] Synergy between amyloid-β and tau in Alzheimer's disease
    Busche, Marc Aurel
    Hyman, Bradley T.
    NATURE NEUROSCIENCE, 2020, 23 (10) : 1183 - 1193
  • [25] Pyroglutamylated amyloid-β is associated with hyperphosphorylated tau and severity of Alzheimer's disease
    Mandler, Markus
    Walker, Lauren
    Santic, Radmila
    Hanson, Peter
    Upadhaya, Ajeet Rijal
    Colloby, Sean J.
    Morris, Christopher M.
    Thal, Dietmar R.
    Thomas, Alan J.
    Schneeberger, Achim
    Attems, Johannes
    ACTA NEUROPATHOLOGICA, 2014, 128 (01) : 67 - 79
  • [26] Plasma Levels of Amyloid-β Peptides and Tau Protein in Mexican Patients with Alzheimer's Disease
    Castillo-Mendieta, Tzayaka
    Arana-Lechuga, Yoaly
    Campos-Pena, Victoria
    Luisa Sosa, Ana
    Orozco-Suarez, Sandra
    Pinto-Almazan, Rodolfo
    Segura-Uribe, Julia
    Rodriguez-Sanchez de Tagle, Aldo Javier
    Ruiz-Sanchez, Elizabeth
    Guerra-Araiza, Christian
    JOURNAL OF ALZHEIMERS DISEASE, 2021, 82 : S271 - S281
  • [27] New therapeutics beyond amyloid-β and tau for the treatment of Alzheimer's disease
    Zhang, Feng
    Zhong, Ru-jia
    Cheng, Cheng
    Li, Song
    Le, Wei-dong
    ACTA PHARMACOLOGICA SINICA, 2021, 42 (09) : 1382 - 1389
  • [28] Amyloid-β and Phosphorylated Tau are the Key Biomarkers and Predictors of Alzheimer's Disease
    Pradeepkiran, Jangampalli Adi
    Baig, Javaria
    Islam, Md Ariful
    Kshirsagar, Sudhir
    Reddy, Hemachandra
    AGING AND DISEASE, 2025, : 658 - 682
  • [29] Cerebrospinal fluid levels of alpha-synuclein, amyloid β, tau, phosphorylated tau, and neuron-specific enolase in patients with Parkinson's disease, dementia with Lewy bodies or other neurological disorders: Their relationships with cognition and nuclear medicine imaging findings
    Katayama, Takayuki
    Sawada, Jun
    Kikuchi-Takeguchi, Shiori
    Kano, Kohei
    Takahashi, Kae
    Saito, Tsukasa
    Okizaki, Atsutaka
    Hasebe, Naoyuki
    NEUROSCIENCE LETTERS, 2020, 715
  • [30] The Dichotomy of Alzheimer's Disease Pathology: Amyloid-β and Tau
    Ashford, J. Wesson
    JOURNAL OF ALZHEIMERS DISEASE, 2019, 68 (01) : 77 - 83